A deficiency in the ability to repair DNA damages could therefore alter the response to treatment with a significant positive association between polymorphism ERCC2 gene, Lys751Gln, but also ERCC1, Asn118Asn with the improved cisplatin response in osteosarcoma [17]. This evidence concerns the gene ERCC2 and osteosarcoma.